Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of calcitriol and tazarotene is a topical treatment used primarily for psoriasis. These two medications work through different mechanisms to reduce psoriatic symptoms, including scaling, plaque elevation, and erythema. Calcitriol is a vitamin D analogue that helps control excessive skin cell production[4]. It's the naturally occurring active form of vitamin D3 and is effective in treating mild to moderate plaque psoriasis. Tazarotene is a topical retinoid that works by keeping skin pores clear and reducing inflammation[10]. It has synergistic effects when combined with other treatments, including vitamin D analogues like calcitriol[7]. Clinical studies have shown that the combination of these medications can be effective for treating mild-to-moderate plaque psoriasis. One study demonstrated that topical treatment with tazarotene 0.1% and calcitriol 0.003% was efficacious in treating mild-to-moderate stable plaque psoriasis (SPP) as both sequential and monotherapy treatments[2]. The combination can be applied in different ways: - Sequential treatment (tazarotene followed by calcitriol or vice versa) - Simultaneous application When used together, these medications show comparable efficacy to potent corticosteroids like clobetasol in reducing psoriatic scaling, plaque elevation, and overall lesional severity[1][6]. This makes them a valuable non-steroidal alternative for psoriasis treatment. Common side effects include: - Itching - Irritation - Burning sensation - Increased erythema However, studies suggest that calcitriol is generally better tolerated than other vitamin D analogues like calcipotriene, with less perilesional erythema, edema, and stinging/burning[6]. Both medications can be combined with UV treatment for enhanced efficacy[6]. Tazarotene should be avoided in patients who are pregnant or trying to become pregnant[7]. This combination represents an important non-steroidal approach to treating psoriasis, particularly valuable for patients who need to avoid long-term corticosteroid use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Calcitriol and Tazarotene (combination).